The Ethics and Responsabilities Charter is derived from the thoughts and reflexions of Roquette employees and seeks to instill throughout the group a strong and dynamic sense of social responsability and corporate citizenship.

Discover the ethical principles and values we all share and to which we have rallied in support of the corporate vision...

Roquette’s advanced research and production have been serving the parenteral preparations market worldwide for a number of decades. The company’s range of products is renowned for its purity and reliability.

Roquette’s active ingredients and excipients have their origins in the abundant harvests of agriculture and are all derived from renewable raw materials.

Roquette offers a comprehensive range of outstandingly pure materials for parenteral preparations:

• Pyrogen-free dextrose monohydrate LYCADEX^® PF
• Pyrogen-free mannitol PEARLITOL^® PF
• Pyrogen-free sorbitol NEOSORB^® PF
• Pyrogen-free organic salt SODIUM GLUCONATE PHARMA
• Parenteral grade hydroxypropyl betacyclodextrin KLEPTOSE^® HPB/HP

This technical documentation describes the outstanding properties of the company's range of products.

 

This user-friendly CD-ROM is a “stand-alone” version of the roquettepharma.com website. Most of the content of this website can be found in the CD-ROM including the Product Finder and the technical brochures.

The Product Finder with its multiple search engine makes it possible to explore our range of products, either by application, functionalities or product family.

Sets out products by application:

• Oral care
• Molecular encapsulation with cyclodextrins
• Injectables
• Syrups, liquids
• Pharmaceutical confectionery
• Nutrition & Health
• Tabletting
  • Direct compression
  • Disintegrants
  • Wet granulation
  • Stable excipients

  For each of the applications listed above, the guide allows you to choose different products by functionality, and by conformity to the main pharmacopeias.

CRYSMEB is a unique low methylated derivative of betacyclodextrin. The degree of methylation is controlled in such a manner that the derivative has an advantageous profile of solubilising power and biological tolerance.

CRYSMEB could be an alternative solution for cyclodextrin-drug formulations.